Meeting
2023 ASCO Annual Meeting
First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.
Authors
Jifang Gong
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology/Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, Beijing, China
Jifang Gong , Jian Zhang , Ning Li , Lin Shen , Lingying Wu , Youzhong Zhang , Yi Huang , Ying Wang , Junyan Wu , Ge Lou , Yaqing Chen , Su-xia Luo , Yi Ba , Xian Wang , Yulong Zheng , Guiling Li , Zhongsheng Tong , Robert Huang , Yan Teng , Xichun Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04740398
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5577)
DOI
10.1200/JCO.2023.41.16_suppl.5577
Abstract #
5577
Poster Bd #
272
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.
First Author: Ning Li
Poster
2023 ASCO Annual Meeting
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
First Author: Mothaffar F. Rimawi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
First Author: Jin Li